Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

THRX - Theseus Pharmaceuticals, Inc.

IEX Last Trade
3.23
-0.080   -2.477%

Share volume: 310,253
Last Updated: Tue 08 Aug 2023 09:59:54 PM CEST
Pharmaceutical Preparation Manufacturing : 2.72%

PREVIOUS CLOSE
CHG
CHG%
$3.31
-0.08
-2.42%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
57%
Profitability 68%
Dept financing 0%
Liquidity 0%
Performance 75%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$3.23
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
44.230 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: Timothy P. Clackson
Region: US
Website: theseusrx.com
Employees: 30
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

Theseus Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of targeted therapies for cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Recent news